EGF receptor (EGFR) and HER2 are two members of the ErbB/HER-family of tyrosine-kinase receptors that are frequently altered in breast cancer and several other malignancies, which inspired the ...

Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...

Trastuzumab, a humanized monoclonal antibody directed against the extracellular domain of the HER2 receptor, and lapatinib, a dual reversible EGFR/HER2 TKI, are indicated for the treatment of HER2 ...

The physician's choice of therapy included Novartis' EGFR/HER2 inhibitor Tykerb (lapatinib) plus Roche's chemotherapeutic drug Xeloda (capecitabine), or Roche's HER2 therapy Herceptin (trastuzumab ...

The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...

The FDA has granted priority review to the new drug application for zongertinib to treat adults with unresectable or metastatic, HER2-mutant NSCLC who have received prior systemic therapy.

DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase inhibitor of the EGFR, which binds irreversibly to certain mutant forms of ...

HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung cancer (NSCLC), typically in female individuals, who are non-smokers, and have ...

including 2L EGFR exon 20 insertion (EGFR exon 20 inhibitor naïve), 2L+ HER2 exon 20 insertion, and 2L+ EGFR atypical mutations. Presented preclinical data demonstrating potential best-in-class ...

ALX Oncology (ALXO) will highlight progress across its clinical pipeline, including continued advancement of investigational CD47-blocker ...

First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC ...

Bayer initiates phase II panSOHO study with BAY 2927088 in metastatic or unresectable HER2 mutant solid tumours: Berlin Wednesday, March 5, 2025, 09:00 Hrs [IST] Bayer announced t ...